Xconomy Boston

Collegium Pharmaceutical, Inc. Lands $20,000,000 Series D Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6f5d478e-63ac-42c4-9e7b-a9c9ffaec05e&Preview=1
Date
7/15/2008
Company Name
Collegium Pharmaceutical, Inc.
Mailing Address
400 Highland Corporate Drive Cumberland, RI 02864
Company Description
Collegium Pharmaceutical is dedicated to the development of proprietary, late stage pharmaceutical products that add market value and clinical benefit to existing drugs. We apply customized pharmaceutical formulations and intellectual property (IP) strategies to drugs that are safe and effective, creating a portfolio of improved pharmaceutical products with a shorter time to market.
Website
http://www.collegiumpharma.com
Transaction Type
Venture Equity
Transaction Amount
$20,000,000
Transaction Round
Series D
Proceeds Purposes
The proceeds from this financing will be used primarily to support the continued development of the Company’s lead DETERx™ product candidate, COL-003, a tamper resistant, abuse-deterrent, sustained release oxycodone formulation.
M&A Terms
Venture Investor
Frazier Healthcare Ventures
Venture Investor
Boston Millennia Partners